In this regard, whether patients who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for left ventricular dysfunction or systolic heart failure), would benefit from the addition of these pharmacotherapies to reduce the risk of future MACE is not known and remains to be tested. The gene discussed is ACE; the disease is hypertensive disorder.